← Back to All US Stocks

Alpha Teknova, Inc. (TKNO) Stock Fundamental Analysis & AI Rating 2026

TKNO Nasdaq In Vitro & In Vivo Diagnostic Substances DE CIK: 0001850902
Updated This Month • Analysis: May 8, 2026 • SEC Data: 2026-03-31
Combined AI Rating
SELL
78% Confidence
N/A
SELL
78% Conf
Pending
Analysis scheduled

📊 TKNO Key Takeaways

Revenue: $11.1M
Net Margin: -41.1%
Free Cash Flow: $-3.6M
Current Ratio: 4.59x
Debt/Equity: 0.20x
EPS: $-0.08
AI Rating: SELL with 78% confidence
Alpha Teknova, Inc. (TKNO) receives a SELL rating with 78% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $11.1M, net profit margin of -41.1%, and return on equity (ROE) of -7.0%, Alpha Teknova, Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete TKNO stock analysis for 2026.

Is Alpha Teknova, Inc. (TKNO) a Good Investment?

Claude

Despite hypergrowth revenue (+5807% YoY), Alpha Teknova is fundamentally unprofitable with negative operating cash flow of -$3.4M and -41.1% net margins. The company is burning cash at -$3.6M free cash flow rate with only ~$4.3M liquidity, creating limited runway. While improving loss trajectory and strong balance sheet provide some upside optionality, the failure to convert explosive revenue growth into positive cash generation signals execution risk.

Why Buy Alpha Teknova, Inc. Stock? TKNO Key Strengths

Claude
  • + Exceptional revenue growth of 5807% YoY demonstrates strong market demand and commercialization progress
  • + Excellent liquidity position with 4.59x current ratio and 3.60x quick ratio provides operational flexibility
  • + Conservative leverage with 0.20x debt/equity ratio and manageable $13.2M long-term debt burden
  • + Improving loss metrics (35.5% reduction in net loss, 43.9% improvement in diluted EPS YoY) suggests trajectory toward profitability
  • + Reasonable 34.2% gross margin indicates product-market fit and viable unit economics

TKNO Stock Risks: Alpha Teknova, Inc. Investment Risks

Claude
  • ! Negative free cash flow of -$3.6M indicates company is burning cash despite revenue growth, unsustainable long-term
  • ! Operating cash flow negative at -$3.4M reveals operational unprofitability and cost structure concerns
  • ! Limited cash runway of approximately 1 period at current -$4.6M quarterly loss rate relative to $4.3M cash position
  • ! Failure to achieve profitability at scale raises questions about unit economics and business model viability
  • ! Risk of equity dilution or additional debt financing required to fund continued operations and growth

Key Metrics to Watch

Claude
  • * Operating cash flow trend - must turn positive within next 2-3 quarters to validate business model
  • * Gross margin sustainability as revenue scales - watch for cost of goods sold inflation
  • * Operating expense growth rate relative to revenue growth - need leverage improvement in SG&A
  • * Quarterly cash burn rate and estimated runway remaining - critical for solvency timeline
  • * Path and timeline to GAAP profitability and positive operating cash flow

Alpha Teknova, Inc. (TKNO) Financial Metrics & Key Ratios

Revenue
$11.1M
Net Income
$-4.6M
EPS (Diluted)
$-0.08
Free Cash Flow
$-3.6M
Total Assets
$98.7M
Cash Position
$4.3M

💡 AI Analyst Insight

Strong liquidity with a 4.59x current ratio provides a solid financial cushion.

TKNO Profit Margin, ROE & Profitability Analysis

Gross Margin 34.2%
Operating Margin -38.8%
Net Margin -41.1%
ROE -7.0%
ROA -4.6%
FCF Margin -32.3%

TKNO vs Healthcare Sector: How Alpha Teknova, Inc. Compares

How Alpha Teknova, Inc. compares to Healthcare sector averages

Net Margin
TKNO -41.1%
vs
Sector Avg 12.0%
TKNO Sector
ROE
TKNO -7.0%
vs
Sector Avg 15.0%
TKNO Sector
Current Ratio
TKNO 4.6x
vs
Sector Avg 2.0x
TKNO Sector
Debt/Equity
TKNO 0.2x
vs
Sector Avg 0.6x
TKNO Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Alpha Teknova, Inc. Stock Overvalued? TKNO Valuation Analysis 2026

Based on fundamental analysis, Alpha Teknova, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-7.0%
Sector avg: 15%
Net Profit Margin
-41.1%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.20x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Alpha Teknova, Inc. Balance Sheet: TKNO Debt, Cash & Liquidity

Current Ratio
4.59x
Quick Ratio
3.60x
Debt/Equity
0.20x
Debt/Assets
34.2%
Interest Coverage
N/A
Long-term Debt
$13.2M

TKNO Revenue & Earnings Growth: 5-Year Financial Trend

TKNO 5-year financial data: Year 2021: Revenue $36.9M, Net Income $3.6M, EPS $0.16. Year 2022: Revenue $41.4M, Net Income -$9.8M, EPS $-0.61. Year 2023: Revenue $41.4M, Net Income -$47.5M, EPS $-1.69. Year 2024: Revenue $37.7M, Net Income -$36.8M, EPS $-1.16. Year 2025: Revenue $40.5M, Net Income -$26.7M, EPS $-0.57.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Alpha Teknova, Inc.'s revenue has shown modest growth of 10% over the 5-year period. The most recent EPS of $-0.57 indicates the company is currently unprofitable.

TKNO Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-32.3%
Free cash flow / Revenue

TKNO Quarterly Earnings & Performance

Quarterly financial performance data for Alpha Teknova, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $9.8M -$4.6M $-0.08
Q3 2025 $9.6M -$4.3M $-0.08
Q2 2025 $9.6M -$3.6M $-0.07
Q1 2025 $9.3M -$4.6M $-0.09
Q3 2024 $8.2M -$7.6M $-0.15
Q2 2024 $9.6M -$5.4M $-0.13
Q1 2024 $9.1M -$8.1M $-0.20
Q3 2023 $8.2M -$10.2M $-0.34

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Alpha Teknova, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$3.4M
Cash generated from operations
Capital Expenditures
$221.0K
Investment in assets
Dividends
None
No dividend program

TKNO SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Alpha Teknova, Inc. (CIK: 0001850902)

📋 Recent SEC Filings

Date Form Document Action
May 7, 2026 10-Q tkno-20260331.htm View →
May 6, 2026 8-K tkno-20260504.htm View →
Apr 21, 2026 DEF 14A tkno-20260421.htm View →
Mar 9, 2026 4 xslF345X05/edgardoc.xml View →
Mar 9, 2026 4 xslF345X05/edgardoc.xml View →

Frequently Asked Questions about TKNO

What is the AI rating for TKNO?

Alpha Teknova, Inc. (TKNO) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.

What are TKNO's key strengths?

Claude: Exceptional revenue growth of 5807% YoY demonstrates strong market demand and commercialization progress. Excellent liquidity position with 4.59x current ratio and 3.60x quick ratio provides operational flexibility.

What are the risks of investing in TKNO?

Claude: Negative free cash flow of -$3.6M indicates company is burning cash despite revenue growth, unsustainable long-term. Operating cash flow negative at -$3.4M reveals operational unprofitability and cost structure concerns.

What is TKNO's revenue and growth?

Alpha Teknova, Inc. reported revenue of $11.1M.

Does TKNO pay dividends?

Alpha Teknova, Inc. does not currently pay dividends.

Where can I find TKNO SEC filings?

Official SEC filings for Alpha Teknova, Inc. (CIK: 0001850902) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is TKNO's EPS?

Alpha Teknova, Inc. has a diluted EPS of $-0.08.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is TKNO a good stock to buy right now?

Based on our AI fundamental analysis in May 2026, Alpha Teknova, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is TKNO stock overvalued or undervalued?

Valuation metrics for TKNO: ROE of -7.0% (sector avg: 15%), net margin of -41.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy TKNO stock in 2026?

Our dual AI analysis gives Alpha Teknova, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is TKNO's free cash flow?

Alpha Teknova, Inc.'s operating cash flow is $-3.4M, with capital expenditures of $221.0K. FCF margin is -32.3%.

How does TKNO compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -41.1% (avg: 12%), ROE -7.0% (avg: 15%), current ratio 4.59 (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% DT 92% DECK 92% DAVEW 92% ANET 88% RDDT 88% KNSL 88% MGRE 88%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 8, 2026 | Data as of: 2026-03-31 | Powered by Claude AI